News & Updates
Filter by Specialty:
Show Multimedia Only

Semaglutide benefits extend to HFpEF patients with T2D
04 May 2024
byElvira Manzano
The weight loss and heart failure (HF) benefits of semaglutide extend to patients with obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D) in the STEP-HFpEF DM trial, fuelling speculation that semaglutide may have cardiovascular effects beyond weight loss.
Semaglutide benefits extend to HFpEF patients with T2D
04 May 2024
Prognosis role of blood urea nitrogen to serum albumin ratio established in IPAH
03 May 2024
A higher ratio of blood urea nitrogen to serum albumin is indicative of worse outcomes and disease severity in patients with idiopathic pulmonary arterial hypertension (IPAH), according to a study.